Perrine Janiaud, PhD; Cathrine Axfors, MD, PhD; Andreas M. Schmitt, MD; Viktoria Gloy, PhD; Fahim Ebrahimi, MD, MSc; Matthias Hepprich, MD; Emily R. Smith, ScD, MPH; Noah A. Haber, ScD; Nina Khanna, MD; David Moher, PhD; Steven N. Goodman, MD, PhD; John P. A. Ioannidis, MD, DSc; Lars G. Hemkens, MD, MPH
In this issue of
JAMA, Janiaud et al
1 present a meta-analysis of randomized clinical trials (RCTs) of convalescent plasma for the treatment of patients with COVID-19. Based on an analysis of 1060 patients from 4 RCTs published in peer-reviewed journals and 10 722 patients from 6 RCTs (5 published as preprints and 1 as a press release), the authors found that treatment with convalescent plasma vs placebo or standard of care was not associated with a significant decrease in all-cause mortality (risk ratio, 0.93 [95% CI, 0.63-1.38] for the 4 peer-reviewed RCTs; risk ratio, 1.02 [95% CI, 0.92-1.12] for all 10 RCTs) or with benefit for other clinical outcom
The Lancet: 3-month interval between first and second dose of Oxford COVID-19 vaccine results in higher vaccine efficacy than 6-week interval
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Arthritis drug Tocilizumab reduces Covid-19 deaths, Plymouth trials show
Patients who take tocilizumab are not only more likely to survive Covid-19, but also tend to spend less time in hospital
Updated
The video will auto-play soon8Cancel
Play now
A trial carried out in South West hospitals has proven the effectiveness of a using an arthritis drug to treat patients suffering from Covid-19.
The RECOVERY research project, which included Plymouth’s Derriford Hospital, has shown that tocilizumab – an anti-inflammatory rheumatoid arthritis treatment – reduces the risk of death for patients suffering from severe effects of the virus.
Researchers also found that the drug reduces the length of hospital admission, and the risk of patients requiring mechanical ventilation.
A clinical trial including patients from Cornwall s hospitals says it has found evidence that an anti-inflammatory rheumatoid arthritis treatment reduces the risk of death for hospitalised patients with severe Covid-19. Researchers with the RECOVERY trial say that tocilizumab also reduces the length of hospital admission, and the risk of patients requiring mechanical ventilation. The RECOVERY trial was the world’s first study to show that dexamethasone – a cheap and available steroid that lowers inflammation in the body – reduces the risk of dying from Covid-19. Now it has gone a step further and found that combining this with with tocilizumab in Covid-19 patients who have significant inflammation reduces mortality by about one third for patients requiring simple oxygen, and nearly one half for those requiring invasive mechanical ventilation.
UK COVID-19 vaccines delivery plan
Updated 13 January 2021 © Crown copyright 2021 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/uk-covid-19-vaccines-delivery-plan/uk-covid-19-vaccines-delivery-plan
Ministerial foreword
We have always known that vaccines would be our best way out of this pandemic and towards a more normal way of life. It is why we moved fast and early: supporting ground-breaking research from January last year, and pre-ordering millions of vaccines on behalf of the whol
vimarsana © 2020. All Rights Reserved.